Arp Inc

Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous and immune systems. It provides clinical development programs for the areas of schizophrenia, obsessive-compulsive disorder, bipolar disorder, multiple sclerosis and lupus. Repligen markets two niche products, Protein A and SecreFlo. Protein A is a consumable reagent used by the pharmaceutical industry to manufacture a class of drugs called monoclonal antibodies. The company offers a number of products based on recombinant Protein A, which include recombinant Protein A, Immobilized Protein A and Protein A ELISA Kits. SecreFlo is approved by the Food and Drug Administration to aid in the diagnosis of pancreatic exocrine dysfunction and gastrinoma and to aid in the identification and cannulation of the pancreatic ducts in patients undergoing endoscopic retrograde cholangiopancreatography. Repligen Corporation was established in 1981 and is headquartered in Waltham, Mass.

Biomodels in Waltham offers a wide range of preclinical research services, specializing in contract services for biopharmaceutical companies. Their experienced team provides comprehensive preclinical CRO services to support the development of innovative therapies and drug candidates. Generated from their website's infomation

Concerto Biosciences, Inc., located in Allston, MA, is at the forefront of harnessing microbial ecology to develop innovative products for skincare and chronic diseases. Their research focuses on translating deep ecological insights into real-world efficacy, particularly in addressing issues like atopic dermatitis and vaginal yeast infections. The company utilizes advanced AI models to predict and engineer microbial communities, ensuring their products perform effectively outside the lab. With a commitment to transforming the microbial world, Concerto aims to create best-in-class solutions that leverage the power of microbes for improved health outcomes. Generated from the website